scholarly journals Excretion rates of 1,5-anhydro-D-glucitol, uric acid and microalbuminuria as glycemic control indexes in patients with type 2 diabetes

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Cong Ma ◽  
Junqin Sheng ◽  
Zhiwen Liu ◽  
Minghao Guo
Keyword(s):  
Type 2 Diabetes ◽  
Uric Acid ◽  
Glycemic Control ◽  
Excretion Rates

scholarly journals Association between serum uric acid and HbA1c in patients with type 2 diabetes mellitus: A case control study in Indian population

2020 ◽  
pp. 4-7
Author(s):  
Indu Verma ◽  
Archana Nimesh
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Uric Acid ◽  
Glycemic Control ◽  
Serum Uric Acid ◽  
Demographic Data ◽  
Males And Females ◽  
Normal Males

Background and Aim: Uric acid is a pro-oxidant molecule that might be implicated in increasing oxidative stress and insulin resistance in type 2 diabetes mellitus patients. Hence, the aim of the study was to assess serum uric acid and HbA1c level (an indicator of glycemic control) in these patients and speculate the association between the two. Methods: 40 newly diagnosed cases of Type 2 diabetes mellitus (20 males and 20 females) with age ranging between 35-70 years were statistically compared against 40 age and sex-matched healthy subjects with respect to their uric acid and HbA1c levels. Demographic data like the height and weight of patients was also recorded and statistically compared. Results: No statistical difference in age, height and weight were observed in type 2 diabetes cases vs. controls indicating that the groups were comparable. HbA1c and uric acid levels of males and females with type 2 diabetes mellitus were significantly higher in comparison to normal males and females(controls). Correlation analysis showed a positive and significant correlation between HbA1c and uric acid levels in male and female cases of type 2 diabetes mellitus Conclusion: Uric acid might have a role in the development or worsening of type 2 diabetes mellitus. However, further studies are required with a larger sample size to clearly establish the relationship between uric acid and glycemic control in type 2 diabetes mellitus since studies in the literature have shown conflicting results and hence the understanding of the etiopathogenesis of type 2 diabetes mellitus remains poorly understood with respect to uric acid. Keywords: type 2 diabetes mellitus; uric acid, HbA1c; etiopathogenesis; correlation.

scholarly journals Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor

Drug Research ◽  
2018 ◽  
Vol 68 (12) ◽  
pp. 704-709 ◽  
Author(s):  
Masataka Kusunoki ◽  
Yukie Natsume ◽  
Tetsuro Miyata ◽  
Kazuhiko Tsutsumi ◽  
Yoshiharu Oshida
Keyword(s):  
Type 2 Diabetes ◽  
Uric Acid ◽  
Glycemic Control ◽  
Serum Lipid ◽  
Sglt2 Inhibitor ◽  
Concomitant Administration ◽  
The Body ◽  
Good Glycemic Control ◽  
Dipeptidyl Peptidase 4

AbstractWe conducted this study to determine whether additional administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor might provide further improvement of the glycemic control in Japanese type 2 diabetes patients showing relatively good glycemic control under treatment with a sodium glucose co-transporter 2 (SGLT2) inhibitor. Five SGLT2 inhibitor (luseogliflozin, dapagliflozin, tofogliflozin, empagliflozin and canagliflozin) preparations and five DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, anagliptin and linagliptin) preparations were used. The results showed that monotherapy with SGLT2 inhibitor produced significant decreases of the body weight and BMI, hemoglobin A1c (HbA1c) also decreased, but not to a significant extent. However, decreases of the serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltransferase (γ-GTP) and uric acid were observed in this group. On the other hand, in type 2 diabetes patients treated concomitantly with a DPP-4 inhibitor and SGLT2 inhibitor, significant decrease of the HbA1c was observed, indicating the favorable effect of the concomitant therapy. The body weight and BMI decreased. As for the serum lipid profile, elevation of the serum HDL-cholesterol (HDL-C) was observed. Furthermore, AST, ALT, γ-GTP and uric acid decreased in the combined treatment group. Then, the therapeutic responses to concurrent administration with SGLT2 inhibitor of each of the 5 individual DPP-4 inhibitors used in this study were analyzed. The results showed that concomitant administration of sitagliptin, a DPP-4 inhibitor, with the SGLT2 inhibitor yielded the best results in terms of the lowering of the HbA1c and improvement of the serum lipid profile.

scholarly journals Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor

Drug Research ◽  
2020 ◽  
Vol 70 (04) ◽  
pp. 131-136
Author(s):  
Masataka Kusunoki ◽  
Daisuke Sato ◽  
Takahiko Sakazaki ◽  
Tetsuro Miyata ◽  
Kazuhiko Tsutsumi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Uric Acid ◽  
Glycemic Control ◽  
Sglt2 Inhibitor ◽  
Serum Levels ◽  
Dipeptidyl Peptidase 4 ◽  
Inhibitor Treatment

AbstractWe conducted this study to determine whether additional administration sodium-glucose co-transporter 2 (SGLT2) inhibitor might provide further improvement of glycemic control and also to explore any advantages in Japanese type 2 diabetes patients showing relatively good glycemic control under treatment dipeptidyl peptidase-4 (DPP-4) inhibitors. We divided the patients in two groups, MT group and CT group. The MT group were continued on the DPP-4 inhibitor treatment for 6-months, and CT group were additionally administered an SGLT2 inhibitor treatment for 6-months. The MT group showed a significant decrease of hemoglobin A1c (HbA1c), but a significant increase of body weight, body mass index and serum uric acid, compared to the baseline values, while the CT group showed a significant decrease of HbA1c, body weight, BMI, and serum uric acid, and also a significant increase of serum HDL-cholesterol and decrease of serum triglyceride levels. Furthermore, this group showed a significant decrease of serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (γ-GTP), which are markers of liver function. These results suggest that the combination therapy is useful, in particular, for the treatment of type 2 diabetes mellitus patients with hyperlipidemia and liver dysfunction. Among the SGLT2 inhibitors added to the DPP-4 inhibitor treatment, the decreases of serum levels of AST, ALT and γ-GTP were particularly significant in the group receiving luseogliflozin, suggesting that the combination of a DPP-4 inhibitor with luseogliflozin is particularly effective for the treatment of type 2 diabetes mellitus patients with liver dysfunction.

Rheumatoid Factor in Type 2 Male Diabetes Mellitus Patients in a Tertiary Care Hospital of Bangladesh

2018 ◽  
Vol 4 (2) ◽  
pp. 58-62
Author(s):  
Roksana Yeasmin ◽  
MA Muttalib ◽  
Kazi Nazneen Sultana ◽  
Nizamul Hoque Bhuiyan ◽  
Md Jamil Hasan Karami ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Uric Acid ◽  
Rheumatoid Factor ◽  
Serum Uric Acid ◽  
Control Group ◽  
Healthy Male ◽  
Male Patients

Background: Type 2 diabetes mellitus is a chronic disease characterized by relative or absolute deficiency of insulin, resulting in glucose intolerance.Objectives: The present study was planned to see the associations of serum uric acid with positive Rheumatoid factor in type 2 male diabetes mellitus patients. Methodology: This case control study was carried out at the department of Biochemistry at Ibrahim Medical College, Dhaka, Bangladesh. The duration of the study was from June 2015 to June 2016 for a period of one year. In this present study, male patients with type 2 diabetes mellitus were taken as case group and age and sex matched healthy male were taken as control group. Rheumatoid factor was measured from the blood of all case and control group respondents. Others blood para meters were also measured for the correlation with the diabetes mellitus patients.Results: In this present study, 110 male patients presented with type 2 diabetes mellitus were recruited as case and age and sex matched healthy male were recruited as control. More rheumatoid factor positive in type 2 DM male patients with the uric acid range between 6.5 to 9.5 mg/dL. The number of patients was 5 out of total 9 rheumatoid factor positive cases. In this study serum uric acid was significantly correlated with rheumatoid factor in type 2 male diabetic patients. Rheumatoid factor positive cases were taking insulin among 9 and it was statistically significantly associated (p<0.001). Conclusion: In this study serum uric acid is significantly associated with positive rheumatoid factor in type 2 male diabetic patients.Journal of Current and Advance Medical Research 2017;4(2):58-62

Sign in / Sign up

Export Citation Format

Share Document